Abstract
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.
【초록키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, Vaccine, Immunity, SARS-CoV, neutralization, mutations, variant, SARS-CoV-2 variant, Infection, Delta, ferritin, omicron, delta variant, SARS-CoV-2 variants, mice, NHPs, Beta, adjuvant, non-human primate, Heterologous, Sarbecoviruses, domain, neutralization titer, SARS-related viruses, NHP, effective, PROTECT, highest, reported, induce, anticipated, pseudovirus, sarbecovirus, 【제목키워드】 Vaccine, SARS-CoV-2 neutralization,